Earning Reports to Watch (Dec 17-21)

In a patent dispute with Citrix (CTXS-Q), which looks like it is going their way but the same thing happen to him or five years ago when one of the judges derailed the whole process. Now back on track, but Citrix has a lot of firepower and money so they can delay it. Long, drawn…

(Formerly Vast Exploration.) ARHT means Augmented Reality Holographic Technology platform. The chairman is Paul Anka. This is going to be three-dimensional things. (Michael Smedley)

Uses their GPS system to figure out where trains are, and to more accurately schedule trains and service vehicles for people working on the rails. Reported on Aug 14 and earnings were down 10%. That was against a 32% increase in sales. In the coming quarter, earnings are expected to be down 75% year-over-year. Great…

Natural gas. Have announced some major deals with Crew Energy (CR-T) and West Energy (WTL-T) in the Montney region of British Columbia. Expects there will be production within the next year. (Mark Lackey)

They are going to merge with a private company. He likes the company. Liquids are more than half the volumes of the company. He has not completed his homework. (Josef Schachter)

Very junior, although it has been around for a long time. It is basically a lot of hype and hope. They are doing some work in Australia, and virtually have no money. Nothing found to date has been feasible, that they can push it forward in a big way. He avoids companies like this like…

Metal foam technology. Have an application where they can put it into armoured vehicles for blast disbursement. Also have some small deals on the architectural side. In this environment he doesn't think people will be paying a whole lot of attention to it. (Peter Hodson)

This has been a very difficult stock. Recently reported a very bad quarter. He would stay away from this one. Inventory has gone up a lot and their margins have fallen. Cut the dividend totally. Thinks they are in a bit of trouble. (Peter Imhof)

(Market Call Minute.)Reversing of bad cholesterol in clinical studies. A little early for him but has potential. Speculative. (Peter Hodson)

Got approval from FDA, but sales are not following through. Running out of cash. Any new financing could dilute stock price further. (Lou Schizas)

Doing a number of things in the animal area. Interested in it. There should be some dramatic catalysts this year. (Hugh Cleland, CFA)

Has procedure for drying food and extracting nutrients from it. It is a science project at this point, but they have good patents. It is a good company with good potential . (James Hodgins)

He has never owned it. They changed the business so much and he wonders if they can turn this into a turnaround story. He is cautious. (Fabrice Taylor)